| Literature DB >> 33673949 |
Abstract
In recent decades, considerable advances have been made in the treatment of heart failure. The main target of heart failure therapy is the inhibition of the sympathetic nervous system and renin-angiotensin-aldosterone system. The angiotensin receptor blockers represent a breakthrough in the treatment of heart failure with a demonstrated effect on reduction of cardiovascular events. However, new perspectives derive from latest drugs developed for diabetes, iron deficiency, and hyperkalemia. New frontiers are also opened to the development of neurohormonal therapies, antagonists of inflammatory mediators, inotropic agents, and cell-based treatments.Entities:
Keywords: Chronic heart failure; Comorbidities; Neurohormonal antagonists; New therapies; Preserved ejection fraction; Reduced ejection fraction
Year: 2021 PMID: 33673949 DOI: 10.1016/j.hfc.2021.01.006
Source DB: PubMed Journal: Heart Fail Clin ISSN: 1551-7136 Impact factor: 3.179